Evropská unie - čeština - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Evropská unie - čeština - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Evropská unie - čeština - EMA (European Medicines Agency)

krka, d.d., novo mesto - atazanavir (as sulfate) - hiv infekce - antivirotika pro systémové použití - atazanavir krka kapsle, současně podáván s nízkou dávkou ritonaviru, je indikován pro léčbu hiv-1 infikovaných dospělých a pediatrických pacientů ve věku 6 let a starších v kombinaci s jinými antiretrovirovými léčivými přípravky. na základě dostupných virologické a klinické údaje od dospělých pacientů, žádný přínos lze očekávat u pacientů s kmeny rezistentní na více inhibitory proteázy (≥ 4 pi mutací). výběr atazanavir krka léčba léčených dospělých a pediatrických pacientů by měla být založena na individuálním testování virové rezistence a na léčbu pacienta historie.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 100mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 140mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 20mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 50mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 70mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 17512 dasatinib - potahovaná tableta - 80mg - dasatinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 17375 erlotinib-hydrochlorid - potahovaná tableta - 100mg - erlotinib